Granting data exclusivity for clinical trials would undermine access to medicines.
A certificate of supplemental protection provides up to two years of additional protection after expiry of a patent.
Confidential documents obtained by Public Eye show that Novartis has threatened Colombia with international investment arbitration under its BIT with Switzerland to avoid the issuance of a compulsory license
Ukraine has settled a dispute with American pharmaceutical company Gilead Sciences Inc., following the company’s pursuit of legal remedies in both domestic courts and via investment arbitration.
A draft of the Regional Comprehensive Economic Partnership agreement reveals three clauses that could potentially hurt production of important generic drugs
Some of the main TRIPS-plus measures historically pushed for by countries such as the United States or the EU are being again proposed at the EU-Mercosur FTA.
Switzerland is pushing for tighter patent protection, data exclusivity and dropping compulsory licencing under a new free trade agreement.
In this note, Switzerland is proposing that India agree to broader patentable subject matter, particularly as regards biologic products.
MSF and civil society urge Swiss negotiators not to undermine the ‘pharmacy of the developing world’
People Over Profit Statement on the 17th Round of Negotiations of the Regional Comprehensive Economic Partnership (RCEP) in Kobe, Japan 27 Feb-3 March 2017
Médecins Sans Frontières (MSF) raises concerns over provisions under negotiation in the RCEP investment chapter that threaten to restrict access to affordable medicines for millions of people
The RCEP Kobe conference is the first round of negotiations this year and the first since U.S. President Donald Trump announced he was canceling America’s participation in the Trans-Pacific Partnership. The Kobe meeting will set the tone for the remaining negotiations this year, however NGO representatives, noted that the TPP would be the elephant in the room.
Concerns remain over the impact of RCEP negotiations on public health and access to medicines.
There is no principled basis for EU’s demand of extending patent protection beyond the period of 20 years.
The intellectual property provisions initiated by Japan and South Korea go far beyond the requirements needed under international trade rules.
The Trans-Pacific Partnership was dead long before Donald Trump signed his executive order. But its damaging aspects, like stringent IP provisions, have just migrated to other agreements
The pace of implementation of Indo-Japan free trade agreement needs to be further enhanced in order to exploit the huge potential of the pact, Commerce and Industry Minister Nirmala Sitharaman said.
Novartis lodged a formal notice of dispute under the Switzerland-Colombia BIT.
Global pharmaceutical companies have successfully lobbied for longer monopolies in trade agreements which have delayed the availability of cheaper medicines, resulting in higher prices.
Canadian pharmaceutical patent owners can expect two substantive changes in the next year following implementation of the Canada–European Union trade agreement